CL2012000493A1 - Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas. - Google Patents

Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas.

Info

Publication number
CL2012000493A1
CL2012000493A1 CL2012000493A CL2012000493A CL2012000493A1 CL 2012000493 A1 CL2012000493 A1 CL 2012000493A1 CL 2012000493 A CL2012000493 A CL 2012000493A CL 2012000493 A CL2012000493 A CL 2012000493A CL 2012000493 A1 CL2012000493 A1 CL 2012000493A1
Authority
CL
Chile
Prior art keywords
benzylpiperazine
alkylamino
ketones
pyridine
procedure
Prior art date
Application number
CL2012000493A
Other languages
English (en)
Spanish (es)
Inventor
Sripathy Venkatraman
Syed Mahmood
Bingidimi I Mobele
Olga Lapina
Kellie Vercoe
Ying Li
Jonathan Salsbury
M Mclaws
Original Assignee
Neuralstem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000493(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralstem Inc filed Critical Neuralstem Inc
Publication of CL2012000493A1 publication Critical patent/CL2012000493A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
CL2012000493A 2009-08-24 2012-02-24 Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas. CL2012000493A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23647709P 2009-08-24 2009-08-24

Publications (1)

Publication Number Publication Date
CL2012000493A1 true CL2012000493A1 (es) 2012-09-28

Family

ID=43649584

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000493A CL2012000493A1 (es) 2009-08-24 2012-02-24 Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas.

Country Status (22)

Country Link
US (2) US9278933B2 (enExample)
EP (1) EP2470182B1 (enExample)
JP (1) JP5727482B2 (enExample)
KR (1) KR101701362B1 (enExample)
CN (2) CN105693601A (enExample)
AU (1) AU2010289802C1 (enExample)
BR (1) BR112012004161B1 (enExample)
CA (1) CA2772080C (enExample)
CL (1) CL2012000493A1 (enExample)
DK (1) DK2470182T3 (enExample)
ES (1) ES2475721T3 (enExample)
HR (1) HRP20140621T1 (enExample)
IL (1) IL218298A (enExample)
IN (1) IN2012DN02370A (enExample)
MX (1) MX2012002335A (enExample)
NZ (1) NZ598891A (enExample)
PL (1) PL2470182T3 (enExample)
PT (1) PT2470182E (enExample)
RU (1) RU2567390C2 (enExample)
SG (1) SG178867A1 (enExample)
SI (1) SI2470182T1 (enExample)
WO (1) WO2011028548A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN02370A (enExample) * 2009-08-24 2015-08-21 Neuralstem Inc
WO2018048927A1 (en) * 2016-09-12 2018-03-15 Neuralstem, Inc. Amelioration of neural deficits associated with diabetes
US20180104240A1 (en) * 2016-10-18 2018-04-19 Neuralstem, Inc. Amelioration of radiation-induced cognitive dysfunction
US10042957B2 (en) 2017-01-12 2018-08-07 Innovationdock, Inc. Devices and methods for implementing dynamic collaborative workflow systems
WO2018148733A1 (en) * 2017-02-13 2018-08-16 Neuralstem, Inc. Amelioration of certain deficiencies due to stroke
CN117377664A (zh) * 2020-12-23 2024-01-09 贝勒医学院 孤儿核受体tlx的小分子调节剂
JP2024520722A (ja) 2021-06-03 2024-05-24 オルト・ニューロサイエンス・インコーポレイテッド 不良な認知を有するうつ病患者の治療方法及びベンジルピペラジン-アミノピリジン剤の恩恵を受ける他の患者の選択
US12208096B2 (en) 2022-12-05 2025-01-28 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent
AU2023391488A1 (en) 2022-12-05 2025-05-22 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent
US12233059B2 (en) 2022-12-05 2025-02-25 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU175075B (hu) * 1977-06-30 1980-05-28 Egyt Gyogyszervegyeszeti Gyar Sposob poluchenija piperazidov piridin-karbonovoj kisloty
JPS54122283A (en) * 1978-03-13 1979-09-21 Sumitomo Chem Co Ltd Novel quinazoline derivative and its preparation
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
DE60330323D1 (de) * 2002-03-29 2010-01-14 Schering Corp Stereoselektive alkylierung von chirale 2-methyl-4-geschützte piperazinen
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
EP1576134B1 (en) * 2002-12-09 2013-03-06 Judith Kelleher-Andersson Method for discovering neurogenic agents
BRPI0414209B8 (pt) * 2003-09-09 2021-05-25 Hoffmann La Roche derivados de 1-(2-amino-benzol)-piperazina, seus processos de preparação e seu uso, e medicamento
EP1828165B1 (en) 2004-10-29 2013-03-20 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
US7754724B2 (en) * 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
AU2006329007A1 (en) * 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
IN2012DN02370A (enExample) * 2009-08-24 2015-08-21 Neuralstem Inc

Also Published As

Publication number Publication date
RU2012111227A (ru) 2013-10-10
HK1172844A1 (en) 2013-05-03
US9278933B2 (en) 2016-03-08
JP2013502462A (ja) 2013-01-24
BR112012004161A2 (pt) 2016-03-29
AU2010289802B2 (en) 2014-10-02
IL218298A0 (en) 2012-04-30
EP2470182A4 (en) 2013-04-24
EP2470182B1 (en) 2014-06-04
PL2470182T3 (pl) 2015-05-29
BR112012004161B1 (pt) 2020-04-07
AU2010289802C1 (en) 2015-04-16
MX2012002335A (es) 2012-07-04
US20160090358A1 (en) 2016-03-31
IL218298A (en) 2017-03-30
US20130005974A1 (en) 2013-01-03
EP2470182A1 (en) 2012-07-04
CN102711764A (zh) 2012-10-03
AU2010289802A1 (en) 2012-04-12
KR20120054642A (ko) 2012-05-30
NZ598891A (en) 2014-05-30
DK2470182T3 (da) 2014-07-21
HRP20140621T1 (hr) 2014-11-21
ES2475721T3 (es) 2014-07-11
JP5727482B2 (ja) 2015-06-03
SI2470182T1 (sl) 2014-10-30
WO2011028548A1 (en) 2011-03-10
US9481649B2 (en) 2016-11-01
CN105693601A (zh) 2016-06-22
SG178867A1 (en) 2012-04-27
IN2012DN02370A (enExample) 2015-08-21
CA2772080A1 (en) 2011-03-10
KR101701362B1 (ko) 2017-02-01
CA2772080C (en) 2017-05-30
PT2470182E (pt) 2014-07-24
RU2567390C2 (ru) 2015-11-10

Similar Documents

Publication Publication Date Title
CL2012000493A1 (es) Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas.
MX2012005358A (es) Procedimiento para la preparacion de etexilato de dabigatran.
TN2011000673A1 (en) Bace inhibitors
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
UA110338C2 (xx) Хімічні сполуки
MY156274A (en) COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
GEP20135933B (en) Compounds as bradykinin b1 antagonists
TN2012000248A1 (en) Novel spiropiperidine compounds
UA104438C2 (uk) Спосіб одержання дабігатрану і його проміжних сполук
UA110626C2 (uk) Спосіб одержання пан-інгібіторів циклінзалежної кінази формули (i), а також проміжні продукти цього процесу одержання
MY160392A (en) Triptolide prodrugs
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
GEP20135960B (en) New method of synthesis of ivabradine and pharmaceutically acceptable acid-additive salts thereof
WO2010102154A3 (en) Biaryl oxyacetic acid compounds
WO2010098583A3 (ko) 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물
UY34386A (es) Método para la producción de ácido láctico
MY156873A (en) Novel forms of a multicyclic compound
PH12016501704A1 (en) Method for producing 2-acyliminopyridine derivative
UA117524C2 (uk) Стимулятори рослин, їх застосування та спосіб стимуляції рослин
MX2013009388A (es) Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl).